Journal of Antimicrobial Chemotherapy (1999) 44, 251-261
© 1999 The British Society for Antimicrobial Chemotherapy
The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
a Beth Israel Deaconess Medical Center, 1Deaconess Road, Boston, MA 02215 b University of Pittsburgh, Pittsburgh, PA c Christiana Care Health Systems, Newark, DE d Allegheny University Hospitals, Hahnemann,Philadelphia, PA, USA e Rhône-Poulenc Rorer Pharmaceuticals, Antony, France f Rhône-Poulenc Rorer Pharmaceuticals, Collegeville, PA, USA
A progressive increase in the incidence of vancomycin resistance in strains of Enterococcus faecium (VREF) has severely constrained treatment options for patients with infection caused by this emerging pathogen. Quinupristin/dalfopristin (Synercid), the first injectable streptogramin antibiotic, is active in vitro against VREF, with an MIC90 of 1.0 mg/L. We studied the clinical efficacy and safety of quinupristin/dalfopristin in the treatment of VREF infection. Two prospective studies were conducted simultaneously. The first enrolled only patients with VREF infection; the second included patients with infection caused by other Gram-positive bacterial pathogens in addition to VREF. Patients were enrolled if they had signs and symptoms of active infection and no appropriate alternative antibiotic therapy. The recommended treatment regimen of quinupristin/dalfopristin was 7.5 mg/kg iv every 8 h for a duration judged appropriate by the investigator. A total of 396 patients with VREF infection were enrolled. The most frequent indications for treatment included intra-abdominal infection, bacteraemia of unknown origin, urinary tract infection, catheter-related bacteraemia, and skin and skin structure infection. This patient population had a high prevalence of severe underlying illness, including a history of diabetes mellitus, transplantation, mechanical ventilation, dialysis, chronic liver disease with cirrhosis and oncological disorders. The mean (± S.D.) duration of treatment was 14.5 ± 10.7 days (range: 1–108). The majority of patients (82.1%) were treated every 8 h, as assessed on day 2 of treatment, while 15.9% were treated every 12 h. The clinical success rate was 73.6% [142/193 clinically evaluable patients; 95% confidence interval (CI): 67.4%, 79.8%], the bacteriological success rate 70.5% (110/156 bacteriologically evaluable patients; 95% CI: 63.4%, 77.7%) and the overall success (both clinical and bacteriological success) rate 65.8% (102/156 bacteriologically evaluable patients; 95% CI: 57.9%, 72.9%). VREF bacteraemia at entry, mechanical ventilation and laparotomy were associated with a worse outcome. Quinupristin/dalfopristin was generally well tolerated. The most common systemic adverse events related to treatment were arthralgias (9.1%) and myalgias (6.6%). Related laboratory abnormalities were infrequent. In these severely ill patients with VREF infection and no other clinically appropriate therapeutic alternatives, quinupristin/dalfopristin demonstrated substantial efficacy and a good nervous system, cardiovascular, gastrointestinal, renal and hepatic tolerability.
* Corresponding author. Tel: 1-617-632-7437; Fax: 1-617-632-7439
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. C. Moellering Jr A 39-Year-Old Man With a Skin Infection JAMA, January 2, 2008; 299(1): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Cox Jr., D. A. Popken, and R. Carnevale Quantifying Human Health Risks from Animal Antimicrobials Interfaces, January 1, 2007; 37(1): 22 - 38. [Abstract] [PDF]
|
|
|
|
 |
|
 S. M. Donabedian, M. B. Perri, D. Vager, E. Hershberger, P. Malani, S. Simjee, J. Chow, E. N. Vergis, R. R. Muder, K. Gay, et al. Quinupristin-Dalfopristin Resistance in Enterococcus faecium Isolates from Humans, Farm Animals, and Grocery Store Meat in the United States J. Clin. Microbiol., September 1, 2006; 44(9): 3361 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Raad, H. A. Hanna, M. Boktour, G. Chaiban, R. Y. Hachem, T. Dvorak, R. Lewis, and B. E. Murray Vancomycin-Resistant Enterococcus faecium: Catheter Colonization, esp Gene, and Decreased Susceptibility to Antibiotics in Biofilm Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5046 - 5050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. I. Raad, H. A. Hanna, R. Y. Hachem, T. Dvorak, R. B. Arbuckle, G. Chaiban, and L. B. Rice Clinical-Use-Associated Decrease in Susceptibility of Vancomycin-Resistant Enterococcus faecium to Linezolid: a Comparison with Quinupristin-Dalfopristin Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3583 - 3585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Raad, R. Hachem, and H. Hanna Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction J. Antimicrob. Chemother., June 1, 2004; 53(6): 1105 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A. Bethea, C. M Walko, and P. A Targos Treatment of Vancomycin-Resistant Enterococcus with Quinupristin/Dalfopristin and High-Dose Ampicillin Ann. Pharmacother., June 1, 2004; 38(6): 989 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Phillips, M. Casewell, T. Cox, B. De Groot, C. Friis, R. Jones, C. Nightingale, R. Preston, and J. Waddell Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data J. Antimicrob. Chemother., January 1, 2004; 53(1): 28 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Butaye, L. A. Devriese, and F. Haesebrouck Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria Clin. Microbiol. Rev., April 1, 2003; 16(2): 175 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Dancer, A. Robb, A. Crawford, and D. Morrison Oral streptogramins in the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections J. Antimicrob. Chemother., March 1, 2003; 51(3): 731 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Moise, A. Forrest, M. C. Birmingham, and J. J. Schentag The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin J. Antimicrob. Chemother., December 1, 2002; 50(6): 1017 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Quinupristin + dalfopristin for infections DTB, February 1, 2002; 40(2): 15 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Wald and M. D. Aronson Update in Hospital Medicine Ann Intern Med, December 18, 2001; 135(12): 1052 - 1060. [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Osmon Antimicrobial Resistance: Guidelines for the Practicing Orthopaedic Surgeon J. Bone Joint Surg. Am., December 1, 2001; 83(12): 1891 - 1901. [Full Text] [PDF]
|
|
|
|
|
|
I. Raad, R. Hachem, H. Hanna, E. Girgawy, K. Rolston, E. Whimbey, R. Husni, and G. Bodey Treatment of Vancomycin-Resistant Enterococcal Infections in the Immunocompromised Host: Quinupristin-Dalfopristin in Combination with Minocycline Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3202 - 3204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Rehm, D. R. Graham, L. Srinath, P. Prokocimer, M.-P. Richard, and G. H. Talbot Successful administration of quinupristin/dalfopristin in the outpatient setting J. Antimicrob. Chemother., May 1, 2001; 47(5): 639 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Rupp, P. D. Fey, and G. M. Longo Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model J. Antimicrob. Chemother., May 1, 2001; 47(5): 705 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Patel, M. S. Rouse, K. E. Piper, and J. M. Steckelberg Linezolid Therapy of Vancomycin-Resistant Enterococcus faecium Experimental Endocarditis Antimicrob. Agents Chemother., February 1, 2001; 45(2): 621 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Verma, A. Dhawan, J. Philpott-Howard, M. Rela, N. Heaton, G. M. Vergani, and J. Wade Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin J. Antimicrob. Chemother., January 1, 2001; 47(1): 105 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rachid, K. Ohlsen, W. Witte, J. Hacker, and W. Ziebuhr Effect of Subinhibitory Antibiotic Concentrations on Polysaccharide Intercellular Adhesin Expression in Biofilm-Forming Staphylococcus epidermidis Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3357 - 3363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Drew, J. R. Perfect, L. Srinath, E. Kurkimilis, M. Dowzicky, G. H. Talbot, and for the Synercid Emergency-Use Study Group Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy J. Antimicrob. Chemother., November 1, 2000; 46(5): 775 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shetty and A. P. R. Wilson Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus J. Antimicrob. Chemother., October 1, 2000; 46(4): 633 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother., September 1, 2000; 46(3): 347 - 350. [Full Text] [PDF]
|
|
|
|
|
|
C. von Eiff, R. R. Reinert, M. Kresken, J. Brauers, and D. Hafner Nationwide German Multicenter Study on Prevalence of Antibiotic Resistance in Staphylococcal Bloodstream Isolates and Comparative In Vitro Activities of Quinupristin-Dalfopristin J. Clin. Microbiol., August 1, 2000; 38(8): 2819 - 2823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Murray Vancomycin-Resistant Enterococcal Infections N. Engl. J. Med., March 9, 2000; 342(10): 710 - 721. [Full Text] [PDF]
|
|
|
|
|
|
B. Bozdogan and R. Leclercq Effects of Genes Encoding Resistance to Streptogramins A and B on the Activity of Quinupristin-Dalfopristin against Enterococcus faecium Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2720 - 2725. [Abstract] [Full Text] [PDF]
|
|